May 4, 2021

Life sciences company GeniPhys adds president and CEO, and board chair

WEST LAFAYETTE, Ind. — GeniPhys Inc., a life sciences company focused on developing and commercializing proprietary collagen material technology developed in Purdue University professor Sherry Harbin’s laboratory, announced Tuesday (May 4) that Andrew S. Eibling has been appointed president and CEO and that attorney R. Matthew Neff has been appointed as chairman of the board of directors.

Eibling brings 35 years of leadership experience in the pharmaceutical, CRO and medtech space, focused on business and corporate development. Most recently, he was vice president of business development and alliance management at Enable Injections. He previously was vice president of Enterprise Alliance Management at Covance. He began his career at Eli Lilly and Co., spending nearly 25 years in multiple roles of increasing responsibility. He has a Bachelor of Science degree in mechanical engineering from Purdue and a Master of Business Administration from Indiana University.

Neff is executive director of Thompson Thrift, a national developer of retail and multifamily housing developments, headquartered in Indianapolis. He previously served as president and CEO of AIT Laboratories Inc. Before that, he was president and CEO of CHV Capital, the venture capital subsidiary of Indiana University Health. He serves on several boards of directors, including Inotiv Inc. (NASDAQ: NOTV) and Hotel Tango Whiskey Inc. 

“I am very excited to join GeniPhys and to help lead the continued development and commercialization of this technology,” Eibling said. “The work that Dr. Harbin and GeniPhys have done to develop a first-of-its-kind collagen polymer formulation and associated biofabrication methods will allow the custom design of collagen materials for a broad variety of tissue restoration and regeneration needs. Our first planned medical product, which represents a scaffold-forming liquid collagen, has the potential to accelerate healing and improve restoration of tissue cavities created by skin ulcers, traumatic injuries and surgical procedures, such as lumpectomies.”

Neff said, “The GeniPhys platform presents a major opportunity to impact a broad range of patient needs due to its versatility and multiple formats. Upon approval by the FDA, I believe these products will provide a significant advancement in tissue restoration and regeneration. I look forward to working with the GeniPhys team to help guide the direction of this company and technology.”

Harbin is a professor in Purdue’s Weldon School of Biomedical Engineering, with a joint appointment within the Department of Basic Medical Sciences in Purdue’s College of Veterinary Medicine. She is the founder of GeniPhys.

 “We are very excited to have Andy and Matt join the GeniPhys team,” she said. “The past few years have seen marked advances in our collagen polymer platform, called Collymer.  With Andy and Matt’s help, we expect to accelerate our commercialization efforts, with a view toward having our initial product available for human use in the next few years.”

About GeniPhys

GeniPhys is an early-stage medical technology company located in Zionsville, Indiana, focused on empowering tissue generation. The company’s Collymer technology is based on research conducted in Sherry Harbin’s lab at Purdue University. Materials prepared from the proprietary collagen polymer promote tissue integration and generation while avoiding inflammation, fibrosis and scarring.  The manufacturing process of Collymers allows the fabrication of multiple formats and tissue replacement types and has demonstrated the ability to deliver pharmaceutical and cell-based therapies.  www.geniphys.com

Media contact: Jim Bush, 765-336-1909, jsbush@purdue.edu

Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, (765) 494-4600

© 2015-21 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by Office of Strategic Communications

Trouble with this page? Disability-related accessibility issue? Please contact News Service at purduenews@purdue.edu.